Clinical Trials
Our lead clinical studies cover various mechanisms of action including direct T-cell engagement, activation of immuno-inflammatory response and targeting tumor-associated stromal fibroblasts.
NG-350A Study
(FORTITUDE)
This study will evaluate the safety, tolerability and preliminary efficacy of NG-350A, either alone or in combination with pembrolizumab, in patients with advanced or metastatic epithelial tumors.
NG-350A Study
(FORTIFY)
This study will evaluate the safety, tolerability and preliminary efficacy of NG-350A in combination with a checkpoint inhibitor, in patients with advanced or metastatic epithelial tumors.
NG-641 Study
(STAR)
The aim of this study is to characterise the safety, tolerability and preliminary efficacy of NG-641 in patients with metastatic or advanced epithelial tumors.
NG-641 Study
(MOAT)
The aim of this study is to characterise the safety and tolerability of neoadjuvant NG-641, as a monotherapy or in combination with pembrolizumab, in patients with surgically resectable squamous cell carcinoma of the head and neck (SCCHN). This study will also explore treatment outcomes and translational markers/assays of viral replication, transgene production and TME reprogramming.
NG-641 Study
(NEBULA)
This study will evaluate the safety, tolerability and preliminary efficacy of
NG-641 in combination with nivolumab, in patients with advanced or metastatic epithelial tumors.